RxDoctor Payments Data

Rebecca Bailey, MD

Pulmonary Disease · Sayre, PANPI 1801866439

Payments from drug & device makers

$1,399in general payments, 2019–2025

Across 71 payments — averaging $19.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$259
  • AstraZeneca$245
  • Boehringer Ingelheim$178
  • Jazz Pharmaceuticals Inc.$152
  • Grifols USA, LLC$119
  • Inspire Medical Systems, Inc.$78
  • plus $367 from 11 others

What the payments were for

  • Food & beverage$1,28492%
  • Education$1158%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,399 in reported general payments places this provider in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$49,436
Medicare patients
316
Services billed
662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,500
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$15,626
Breo ElliptaFluticasone/Vilanterol30$14,510
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$12,383
Spiriva RespimatTiotropium Bromide17$11,514
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$5,274
Albuterol Sulfate HfaAlbuterol Sulfate50$1,601
Modafinil13$288
Fluticasone Propionate11$121
Pantoprazole Sodium16$82
Prednisone13$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$259$48,39373 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$178$27,14034 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →